SSMC adds 2 robotic joint surgery systems as Abu Dhabi orthopaedics race tightens

Sheikh Shakhbout Medical City has added two robotic systems for hip and knee replacement surgery in Abu Dhabi, expanding a robotic surgery programme that now spans four systems across multiple specialties.

The move matters first to COOs and CFOs at UAE hospitals and day surgery operators. Robotic joint replacement changes theatre planning, surgeon credentialing, implant procurement, payer pre-authorisation and rehabilitation pathways. For patients, the practical question is narrower: whether the extra technology changes eligibility, recovery time, out-of-pocket cost or insurer approval.

What SSMC has added

Gulf News reported the expansion after SSMC, a PureHealth subsidiary, announced its first robotic-assisted knee and hip replacement procedures in August 2026. A WAM version of the announcement said the systems support personalised joint replacement planning and more accurate implant positioning. The original report is available through Gulf News, and SSMC’s earlier robotic programme history is listed on SSMC.

“The introduction of two new robotic systems for hip and knee replacement represents an important expansion of our capabilities within orthopaedics.” — Dr Abdulqader Almessabi, Chief Medical Officer, SSMC

The hospital said one knee replacement patient had lived with chronic knee pain for more than 30 years. A separate industry report on the same announcement said the patient walked independently within 10 days after surgery. Operators should treat that as a case example, not a benchmark. Recovery after arthroplasty depends on age, body mass, diabetes status, implant choice, surgical approach and physiotherapy adherence.

Why Dubai clinics should watch Abu Dhabi

Dubai remains the first comparison market because private hospitals there already use robotic surgery as a patient-acquisition signal. Dubai Health Authority (DHA) regulates Dubai facilities and professional licensing. Department of Health Abu Dhabi (DOH Abu Dhabi) regulates SSMC and Abu Dhabi providers. Ministry of Health and Prevention (MOHAP) regulates federal facilities and many providers in the northern emirates.

For a Dubai clinic or hospital, the SSMC announcement raises a competitive question: whether robotic orthopaedics should remain a tertiary-hospital service or become a premium elective pathway. Public package prices give a rough commercial frame. Mediclinic lists international patient packages of AED 75,000 for total knee arthroplasty and AED 75,000 for total hip arthroplasty, each with a two-day inpatient duration for normal cases. Clemenceau Medical Center Hospital Dubai lists a total knee replacement package at AED 85,000, including a three-night stay.

• COOs should check whether robotic cases require separate theatre slots, trained scrub teams, vendor support and post-operative physiotherapy capacity.
• CFOs should compare implant, consumable, maintenance and service-contract costs against case volume and payer reimbursement.
• Medical directors should require surgeon privileging criteria, conversion protocols and audit data for infection, revision, readmission and patient-reported outcomes.
• CIOs should confirm whether robot planning data, imaging and operative notes can be captured in the hospital EHR without manual re-entry.

Insurers and patients will decide adoption

Robotic surgery is easier to market than to reimburse. UAE insurers usually assess joint replacement through medical necessity, network status, policy limits and pre-authorisation. Providers should not assume a robotic approach is covered because conventional arthroplasty is covered. Finance teams should ask each payer for the approved tariff, implant rules, consumable exclusions and whether the robotic component is bundled or billed separately.

In Abu Dhabi, Daman and Thiqa are the relevant payer names to check for many residents, but approval still depends on member category and benefit design. In Dubai, providers should check contracts with insurers such as Sukoon only where the patient’s plan is active in the facility network. A practical eligibility screen should include radiographic osteoarthritis grade, failed conservative treatment, anaesthesia fitness, BMI-related risk, infection risk and willingness to complete physiotherapy for six to 12 weeks.

The near-term test is volume. If SSMC can publish annual robotic arthroplasty numbers, readmission rates, revision rates and average length of stay by 2027, competitors will have a clearer benchmark. Until then, UAE operators should evaluate robotic joint replacement as a service-line decision, not a procurement trophy. Patients comparing licensed orthopaedic clinics and hospitals can start with the UAE Open Healthcare Directory to verify providers before requesting payer pre-authorisation.